Hypnotic use for insomnia management in chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and morbidity worldwide. Because of the chronic nature of the disease, optimal care for patients includes successful treatment of comorbidities that accompany COPD, including insomnia. Insomnia symptoms and associated disruption of sleep are prevalent in COPD patients but treatment with traditional benzodiazepines may compromise respiratory function. This review summarizes the efficacy and safety consideration of current drugs available for the treatment of insomnia in COPD patients including benzodiazepines, non-benzodiazepine receptor agonists such as eszopiclone, zolpidem, and zaleplon, sedating antidepressants such as trazodone, and the melatonin receptor agonist ramelteon.
Roth
Thomas
T
Sleep Disorders and Research Center, Henry Ford Hospital, 2799 West Grand Boulevard, CFP-3 Detroit, MI 48202, USA. Troth1@hfhs.org
D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage* / Q000009:adverse effects*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications* / Q000188:drug therapy*
D006993:Hypnotics and Sedatives